



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Ries, U. J. et al ) Art Unit: 1614  
U.S. Appln. No. : 10/050,376 ) Examiner:  
U.S. Filing Date : 01/16/2002  
Confirmation No. : 6171  
Title of Invention : Antithrombotic Compounds  
Attny. Docket No. : 5/1312

1614  
9  
1614  
RECEIVED  
APR 17 2003  
TECH CENTER 1600/2200

Commissioner for Patents  
Washington, D.C. 20231

April 11, 2003

TRANSMITTAL LETTER FOR SECOND INFORMATION DISCLOSURE  
STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow together with a copy of the International Search Report.

☒ 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

☐ A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No.

☐ 1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).

☐ 1.97(e).

☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or

☐ No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,




Susan K. Pocchiari  
Attorney for Applicant(s)  
Reg. No. 45,016

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-5648

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on April 11, 2003



By: Susan K. Pocchiari

Reg. No. 45,016

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

|       |   |    |   |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/050,376       |
| Filing Date            | January 16, 2002 |
| First Named Inventor   | Ries, U. et al   |
| Art Unit               | 1614             |
| Examiner Name          |                  |
| Attorney Docket Number | 5/1312           |

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS |          |   |                  |   |   |                |
|--------------------------|----------|---|------------------|---|---|----------------|
| Examiner Initials*       | Cite No. | Foreign Patent Document   | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | 1 <sup>6</sup> |
|                          |          | Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known) | MM-DD-YYYY       |   |   |                |
|                          |          | WO 96/40100   | 12-19-1996       | 3-Dimensional Pharm.                            |   |                |
|                          |          | WO 00/56707   | 09-28-2000       | Sepracor, Inc.                                  |   |                |
|                          |          | WO 02/04403 A1  | 01-17-2002       | Boehringer Ingelheim                            |   |                |
|                          |          | GB 2007663  | 05-23-1979       | VEB Arzneimittelwerk                            |   |                |
|                          |          | EP 0654465  | 05-24-1995       | CIBA-GEIGY AG                                   |   |                |
|                          |          |   |                  |   |   |                |

|                       |  |                    |  |
|-----------------------|--|--------------------|--|
| Examiner<br>Signature |  | Date<br>Considered |  |
|-----------------------|--|--------------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



|   |   |    |                          |                        |        |
|---|---|----|--------------------------|------------------------|--------|
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br>(Use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |        |
|   |   |    | Application Number       | 10/050,376             |        |
|   |   |    | Filing Date              | January 16, 2002       |        |
|   |   |    | First Named Inventor     | Ries, U. et al         |        |
|   |   |    | Art Unit                 | 1614                   |        |
|   |   |    | Examiner Name            |                        |        |
| Sheet   | 2 | of | 2                        | Attorney Docket Number | 5/1312 |

RECEIVED  
APR 17 2003  
TECH CENTER 1600/2900

| OTHER PRIOR ART–NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---|-----------------------|---|----------------|
| Examiner Initials*                              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|   |                       | LABES, D. and HAGEN, V. "Free-Wilson-Analyse der Hemmwirkung von 4-substituierten Benzamidinen gegenueber Thrombin, Plasmin und Trypsin" Pharmazie, 1979, 34(9):554-555   |                |
|   |                       | TAMIZ, A.P. et al "A Convenient Procedure for the Syntheses of Nonsymmetrical Bivalent Selective Serotonin Reuptake Inhibitors Using Polymer-Supported Reagents" Bioorganic & Med. Chem. Ltrs, 2000, 10:2741-2743.  |                |
|   |                       | VALENTI, et al, "Cyclovinylogs of procainamide" Chemical Abstracts, 1983, 98(7):620   |                |
|   |                       | Database Crossfire Beilstein, Beilstein Institutue Zur Foerderung Der Chemischen Wissenschaften, Frankfurt AM Main, DE  |                |
|   |                       |   |                |
|   |                       |   |                |
|   |                       |   |                |
|   |                       |   |                |
|   |                       |   |                |
|   |                       |   |                |
|   |                       |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.